08:00 , Mar 7, 2005 |  BioCentury  |  Finance

Ebb & Flow

Aspreva's IPO on Thursday evening and subsequent stock pop on Friday suggest that many investors are willing to treat the suspension of multiple sclerosis drug Tysabri as a company-specific event. Indeed, the IPO was a...
02:32 , Mar 5, 2005 |  BC Extra  |  Financial News

Neurochem raises $61.2 million

Neurochem (TSE:NRM; NRMX) raised US$61.2 million through the sale of 4 million shares at US$15.30 in a follow-on underwritten by UBS; CIBC; Piper Jaffray; Desjardins; Wells Fargo Securities; BMO Nesbitt Burns; and Fortis. NRMX proposed...
07:00 , Oct 18, 2004 |  BioCentury  |  Finance

Ebb & Flow

Investors in PharmAthene's $50 million series B round are betting that there's more than the conventional cost-plus 10% in government biodefense contracts. PharmAthene, which is essentially a biodefense play, has an anthrax therapeutic in preclinical...
08:00 , Mar 9, 2004 |  BC Extra  |  Financial News

Aspreva raises $53 million

Aspreva raised $53 million in a series A round led by Sprout Group. Other investors included InterWest; HBM Partners; Thomas Weisel Healthcare Ventures; BioAsia Investments; and Axiom Venture Partners. Aspreva (Victoria, B.C.) issued an additional...
07:00 , Sep 26, 2003 |  BC Extra  |  Top Story

Angiotech raises $218.8 million

Cardiovascular company Angiotech (TSE:ANP; ANPI) raised $218.8 million in a follow-on through the sale of 5 million shares at $43.75. The deal, which has a 750,000 share overallotment, was underwritten by Merrill Lynch; Lehman; BMO...
07:00 , Sep 22, 2003 |  BioCentury  |  Finance

Ebb & Flow

After rushing to the SEC to file S-1s, bankers are taking a wait-and-see approach before actually marketing biotech IPOs. That's because no one wants to be the first to test the waters. A weak response...
07:00 , Sep 18, 2003 |  BC Extra  |  Financial News

Angiotech files for follow-on

Cardiovascular company Angiotech (TSE:ANP; ANPI) filed to sell 5 million shares in a follow-on to be underwritten by Merrill Lynch; Lehman; BMO Nesbitt Burns; and CS First Boston Canada. If the shares are sold in...
07:00 , Aug 4, 2003 |  BioCentury  |  Finance

Ebb & Flow

Scott Sacane, who manages the Durus group of funds, has been a long-term fan of Esperion , although the extent of the stock purchases disclosed in an SEC filing last Tuesday probably were not what...
07:00 , Jul 21, 2003 |  BioCentury  |  Finance

Ebb & Flow

While bankers wait for the IPO levy to break, they remain busy stuffing follow-on paper into the queue. Including the deal filed by Esperion (ESPR) after market on the prior Friday, three significantly sized deals...
07:00 , Jul 17, 2003 |  BC Extra  |  Financial News

Inex raises C$25.1 million

Cancer company Inex (TSE:IEX) raised C$25.1 million (US$18.2 million) in a follow-on through the sale of 4.6 million shares at C$5.45. The deal, which has a 690,000 share overallotment, was underwritten by BMO Nesbitt Burns;...